drugset / Trial / NCT03419403
UNITE Study: Understanding New Interventions With GBM ThErapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).
Timeline
- Start
- 2018-07-30
- Primary completion
- 2019-09-05
- Completion
- 2020-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Depatuxizumab mafodotin | Other / unclassified | 1.25 mg/kg | Intravenous |
| Background | Temozolomide | Small molecule | — | — |